Literature DB >> 19024603

Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines.

Mariusz Adam Goscinski1, Zhen He Suo, Jahn Marthin Nesland, Vivi Ann Flørenes, Karl-Erik Giercksky.   

Abstract

Dipeptidyl peptidase IV (DPPIV) is a transmembrane serine protease which is involved in the process of tumor invasion and development of metastases in human cancers. The aim of this study was to investigate the expression of DPPIV in cancer and stromal cells of both esophageal adenocarcinoma and squamous cell carcinoma (SCC). Tissue material from 159 patients was analyzed using immunohistochemistry. Western blotting was performed on cell lines and fresh frozen tissue sections. Results were compared with clinicopathological features. Evaluation of the immunohistochemical findings revealed significant differences between DPPIV expression in carcinoma cells and stromal cells, depending on the histological tumor type. A significantly higher level of DPPIV was found in adenocarcinomas compared to SCCs while no DPPIV was detected in normal esophageal epithelium. Overexpression of DPPIV in patients with adenocarcinoma was additionally associated with distant metastases. Thus, differences of DPPIV level in esophageal carcinomas compared with normal epithelium showed that esophageal malignancies were associated with an increased amount of cell surface-bound DPPIV. Radiotherapy in patients had no impact on DPPIV expression in analyzed tissue samples. There was no correlation between DPPIV expression in cancer or stromal cells and survival of the patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19024603     DOI: 10.1111/j.1600-0463.2008.01029.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  10 in total

1.  Expression levels of seprase/FAPα and DPPIV/CD26 in epithelial ovarian carcinoma.

Authors:  Mengzhen Zhang; Liwei Xu; Xiaoling Wang; Beibei Sun; Juan Ding
Journal:  Oncol Lett       Date:  2015-04-27       Impact factor: 2.967

2.  Stromal expression of CD34, α-smooth muscle actin and CD26/DPPIV in squamous cell carcinoma of the skin: a comparative immunohistochemical study.

Authors:  Ayper Kacar; Ata Türker Arikok; Tuba Dilay Kokenek Unal; Evrim Onder; Sema Hucumenoglu; Murat Alper
Journal:  Pathol Oncol Res       Date:  2011-06-15       Impact factor: 3.201

Review 3.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

Review 4.  Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?

Authors:  Petr Busek; Jonathan S Duke-Cohan; Aleksi Sedo
Journal:  Cancers (Basel)       Date:  2022-04-21       Impact factor: 6.575

5.  Rapid and sensitive detection of early esophageal squamous cell carcinoma with fluorescence probe targeting dipeptidylpeptidase IV.

Authors:  Haruna Onoyama; Mako Kamiya; Yugo Kuriki; Toru Komatsu; Hiroyuki Abe; Yosuke Tsuji; Koichi Yagi; Yukinori Yamagata; Susumu Aikou; Masato Nishida; Kazuhiko Mori; Hiroharu Yamashita; Mitsuhiro Fujishiro; Sachiyo Nomura; Nobuyuki Shimizu; Masashi Fukayama; Kazuhiko Koike; Yasuteru Urano; Yasuyuki Seto
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

6.  Fibroblast activating protein-α expression in squamous cell carcinoma of the esophagus in primary and irradiated tumors: the use of archival FFPE material for molecular techniques.

Authors:  Renata Tabola; Magdalena Zaremba-Czogalla; Dagmara Baczynska; Roberto Cirocchi; Kamila Stach; Krzysztof Grabowski; Katarzyna Augoff
Journal:  Eur J Histochem       Date:  2017-06-20       Impact factor: 3.188

7.  High expression of uPA related to p38MAPK in esophageal cancer indicates poor prognosis.

Authors:  Qilong Liu; Wenfeng Li; Shibin Yang; Zhaoguo Liu
Journal:  Onco Targets Ther       Date:  2018-11-29       Impact factor: 4.147

8.  Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo.

Authors:  Ivana Z Matić; Marija Ðorđić; Nađa Grozdanić; Ana Damjanović; Branka Kolundžija; Aleksandra Erić-Nikolić; Radan Džodić; Miomir Šašić; Srđan Nikolić; Danijela Dobrosavljević; Sanvila Rašković; Slađana Andrejević; Dušica Gavrilović; Oscar J Cordero; Zorica D Juranić
Journal:  BMC Immunol       Date:  2012-08-21       Impact factor: 3.615

9.  Differential Expression and Enzymatic Activity of DPPIV/CD26 Affects Migration Ability of Cervical Carcinoma Cells.

Authors:  Aline Beckenkamp; Júlia Biz Willig; Danielle Bertodo Santana; Jéssica Nascimento; Juliano Domiraci Paccez; Luiz Fernando Zerbini; Alessandra Nejar Bruno; Diogo André Pilger; Márcia Rosângela Wink; Andréia Buffon
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

10.  A poor prognosis in human hepatocellular carcinoma is associated with low expression of DPP4.

Authors:  Hao Yu; Xiao-Ping Mei; Peng-Fei Su; Guang-Zhi Jin; Hong-Kun Zhou
Journal:  Braz J Med Biol Res       Date:  2020-04-09       Impact factor: 2.590

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.